Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TREATMENT OF NON-SMALL-CELL LUNG-CANCER WITH PROLONGED ORAL ETOPOSIDE
Autore:
KAKOLYRIS S; SAMONIS G; KOUKOURAKIS M; VLACHONICOLIS I; CHALKIADAKIS G; KALBAKIS K; SOUGLAKOS I; AGELAKI S; TOLOUDIS P; GEORGOULIAS V;
Indirizzi:
UNIV GEN HOSP HERAKLION,DEPT MED ONCOL,POB 1352 IRAKLION 71110 GREECE UNIV CRETE,DEPT MED ONCOL,SCH MED IRAKLION 71110 GREECE UNIV CRETE,DEPT RADIOTHERAPY,SCH MED IRAKLION 71110 GREECE UNIV CRETE,SCH MED,DEPT SOCIAL MED IRAKLION 71110 GREECE UNIV CRETE,SCH MED,DEPT THORAC SURG IRAKLION 71110 CRETE GREECE
Titolo Testata:
American journal of clinical oncology
fascicolo: 5, volume: 21, anno: 1998,
pagine: 505 - 508
SICI:
0277-3732(1998)21:5<505:TONLWP>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II TRIAL; CHEMOTHERAPY;
Keywords:
ETOPOSIDE; NON-SMALL-CELL LUNG CANCER; ORAL CHEMOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
18
Recensione:
Indirizzi per estratti:
Citazione:
S. Kakolyris et al., "TREATMENT OF NON-SMALL-CELL LUNG-CANCER WITH PROLONGED ORAL ETOPOSIDE", American journal of clinical oncology, 21(5), 1998, pp. 505-508

Abstract

The efficacy and toxicity of chronic administration of oral etoposidewas evaluated in 61 patients with inoperable nonsmall-cell lung cancer (NSCLC). Ten patients received previous chemotherapy, 15 received radiotherapy, and one received both treatments. Twenty-four patients hadconcurrent cardiac and/or pulmonary impairment, which precluded more intensive treatment. Etoposide was given orally, 100 mg daily for 7 consecutive days and consequently 100 mg every other day for 14 more days in a 28-day schedule. Partial response was observed in 17 patients (28%; 95% confidence interval, 17-39%) and stable disease in 21 (34%). The median duration of response was 6 months (range, 2-34 months). Themedian survival for responders was 22 months and that of nonresponders was 7 months (p < 0.001). The median survival for all patients was 9months (range, 1-35 months; 95% confidence interval, 5.69-12.31%). Toxicity was acceptable. Other than alopecia, which was observed in all patients, myelotoxicity was the most common toxicity-particularly leukopenia, which was severe in nine patients. Other less common toxicities included nausea and vomiting, stomatitis, anorexia, and neurotoxicity and were mild. No treatment-related deaths were observed. In conclusion, the regimen was effective and well tolerated with significant survival benefit for the responders. It represents an interesting therapeutic approach, especially in the elderly.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 16:19:49